Molecular cytogenetics and immunophenotype characteristics of newly diagnosed MM with measurable disease and with oligosecretory, nonsecretory, nonproducer myeloma
| Patients’ characteristics . | Oligosecretory myeloma (N = 61), n/N (%) . | Nonsecretory myeloma (N = 19), n/N (%) . | Nonproducer myeloma (N = 7), n/N (%) . | Measurable disease (N = 735), n/N (%) . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Bortezomib (N = 30) . | Thalidomide (N = 31) . | Bortezomib (N = 6) . | Thalidomide (N = 13) . | Bortezomib (N = 3) . | Thalidomide (N = 4) . | Bortezomib (N = 280) . | Thalidomide (N = 455) . | ||
| Cytogenetic abnormalities | .053 | ||||||||
| Diploidy | 26/53 (49.06) | 13/53 (24.53) | 2/14 (14.29) | 8/14 (57.14) | 2/6 (33.33) | 2/6 (33.33) | 205/563 (36.41) | 262/563 (46.54) | |
| Hyperdiploidy | 1/53 (1.89) | 1/53 (1.89) | 0/14 (0.00) | 0/14 (0.00) | 0/6 (0.00) | 0/6 (0.00) | 8/563 (1.42) | 19/563 (3.37) | |
| Hypodiploidy | 1/53 (0.00) | 0/53 (0.00) | 0/14 (0.00) | 0/14 (0.00) | 0/6 (0.00) | 0/6 (0.00) | 20/563 (3.55) | 19/563 (3.37) | |
| FISH | |||||||||
| del(13q) | 18/59 (30.51) | 9/5 9(15.25) | 2/15 (13.33) | 4/15 (26.67) | 0/5 (0.00) | 0/5 (0.00) | 111/537 (20.67) | 99/537 (18.44) | .733 |
| del(17p) | 3/57 (5.26) | 2/57 (3.51) | 1/15 (6.67) | 1/15 (6.67) | 0/6 (0.00) | 0/6 (0.00) | 19/541 (3.51) | 19/541 (3.51) | .585 |
| 1q21 gains | 19/53 (35.85) | 7/53 (13.21) | 2/15 (13.33) | 3/15 (0.2) | 0/5 (0.00) | 0/5 (0.00) | 94/514 (18.29) | 85/514 (16.54) | .691 |
| IgH translocations | |||||||||
| t(11;14) | 7/49 (14.29) | 4/49 (8.16) | 2/14 (14.29) | 2/14 (14.29) | 1/5 (20.00) | 1/5 (20.00) | 42/532 (7.89) | 32/532 (6.02) | .047 |
| t(4;14) | 5/43 (11.63) | 4/43 (9.30) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 47/529 (8.88) | 31/529 (5.86) | .711 |
| t(14;16) | 2/46 (4.35) | 0/46 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 9/513 (1.75) | 4/513 (0.78) | .449 |
| Immunophenotype | |||||||||
| CD56 positive | 16/57 (28.07) | 9/57 (15.79) | 1/18 (5.56) | 4/18 (22.22) | 0/7 (0.00) | 1/7 (14.29) | 209/679 (30.78) | 187/679 (27.54) | .128 |
| CD20 positive | 1/53 (1.89) | 0/53 (0.00) | 0/19 (0.00) | 3/19 (15.79) | 1/6 (16.67) | 0/6 (0.00) | 42/634 (6.62) | 51/634 (8.04) | .047 |
| CD117 positive | 6/54 (11.11) | 4/54 (7.41) | 0/18 (0.00) | 2/18 (11.11) | 1/7 (14.29) | 0/7 (0.00) | 105/629 (16.69) | 84/629 (13.35) | .785 |
| CD79a positive | 0/54 (0.00) | 0/54 (0.00) | 0/17 (0.00) | 0/17 (0.00) | 0/6 (0.00) | 0/6 (0.00) | 3/607 (0.49) | 8/607 (1.32) | .603 |
| CD33 positive | 0/52 (0.00) | 0/52 (0.00) | 0/16 (0.00) | 0/16 (0.00) | 0/5 (0.00) | 0/5 (0.00) | 24/679 (3.53) | 19/679 (2.80) | .909 |
| CD19 positive | 1/57 (1.75) | 1/57 (1.75) | 0/18 (0.00) | 0/18 (0.00) | 0/7 (0.00) | 1/7 (14.29) | 10/529 (1.89) | 14/529 (2.65) | .057 |
| Patients’ characteristics . | Oligosecretory myeloma (N = 61), n/N (%) . | Nonsecretory myeloma (N = 19), n/N (%) . | Nonproducer myeloma (N = 7), n/N (%) . | Measurable disease (N = 735), n/N (%) . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Bortezomib (N = 30) . | Thalidomide (N = 31) . | Bortezomib (N = 6) . | Thalidomide (N = 13) . | Bortezomib (N = 3) . | Thalidomide (N = 4) . | Bortezomib (N = 280) . | Thalidomide (N = 455) . | ||
| Cytogenetic abnormalities | .053 | ||||||||
| Diploidy | 26/53 (49.06) | 13/53 (24.53) | 2/14 (14.29) | 8/14 (57.14) | 2/6 (33.33) | 2/6 (33.33) | 205/563 (36.41) | 262/563 (46.54) | |
| Hyperdiploidy | 1/53 (1.89) | 1/53 (1.89) | 0/14 (0.00) | 0/14 (0.00) | 0/6 (0.00) | 0/6 (0.00) | 8/563 (1.42) | 19/563 (3.37) | |
| Hypodiploidy | 1/53 (0.00) | 0/53 (0.00) | 0/14 (0.00) | 0/14 (0.00) | 0/6 (0.00) | 0/6 (0.00) | 20/563 (3.55) | 19/563 (3.37) | |
| FISH | |||||||||
| del(13q) | 18/59 (30.51) | 9/5 9(15.25) | 2/15 (13.33) | 4/15 (26.67) | 0/5 (0.00) | 0/5 (0.00) | 111/537 (20.67) | 99/537 (18.44) | .733 |
| del(17p) | 3/57 (5.26) | 2/57 (3.51) | 1/15 (6.67) | 1/15 (6.67) | 0/6 (0.00) | 0/6 (0.00) | 19/541 (3.51) | 19/541 (3.51) | .585 |
| 1q21 gains | 19/53 (35.85) | 7/53 (13.21) | 2/15 (13.33) | 3/15 (0.2) | 0/5 (0.00) | 0/5 (0.00) | 94/514 (18.29) | 85/514 (16.54) | .691 |
| IgH translocations | |||||||||
| t(11;14) | 7/49 (14.29) | 4/49 (8.16) | 2/14 (14.29) | 2/14 (14.29) | 1/5 (20.00) | 1/5 (20.00) | 42/532 (7.89) | 32/532 (6.02) | .047 |
| t(4;14) | 5/43 (11.63) | 4/43 (9.30) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 47/529 (8.88) | 31/529 (5.86) | .711 |
| t(14;16) | 2/46 (4.35) | 0/46 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 9/513 (1.75) | 4/513 (0.78) | .449 |
| Immunophenotype | |||||||||
| CD56 positive | 16/57 (28.07) | 9/57 (15.79) | 1/18 (5.56) | 4/18 (22.22) | 0/7 (0.00) | 1/7 (14.29) | 209/679 (30.78) | 187/679 (27.54) | .128 |
| CD20 positive | 1/53 (1.89) | 0/53 (0.00) | 0/19 (0.00) | 3/19 (15.79) | 1/6 (16.67) | 0/6 (0.00) | 42/634 (6.62) | 51/634 (8.04) | .047 |
| CD117 positive | 6/54 (11.11) | 4/54 (7.41) | 0/18 (0.00) | 2/18 (11.11) | 1/7 (14.29) | 0/7 (0.00) | 105/629 (16.69) | 84/629 (13.35) | .785 |
| CD79a positive | 0/54 (0.00) | 0/54 (0.00) | 0/17 (0.00) | 0/17 (0.00) | 0/6 (0.00) | 0/6 (0.00) | 3/607 (0.49) | 8/607 (1.32) | .603 |
| CD33 positive | 0/52 (0.00) | 0/52 (0.00) | 0/16 (0.00) | 0/16 (0.00) | 0/5 (0.00) | 0/5 (0.00) | 24/679 (3.53) | 19/679 (2.80) | .909 |
| CD19 positive | 1/57 (1.75) | 1/57 (1.75) | 0/18 (0.00) | 0/18 (0.00) | 0/7 (0.00) | 1/7 (14.29) | 10/529 (1.89) | 14/529 (2.65) | .057 |